REACH and in silico methods: An attractive opportunity for medicinal chemists

Drug Discovery Today

Volumn 19, Issue 11, 2014, Pages 1757-1768

  Nicolotti, Orazio ^a   Benfenati, Emilio ^b   Carotti, Angelo ^a   Gadaleta, Domenico ^a   Gissi, Andrea ^a   Mangiatordi, Giuseppe Felice ^a   Novellino, Ettore ^c  

^a UNIVERSITY OF BARI   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ENDOCRINE DISRUPTOR; XENOBIOTIC AGENT; NANOMATERIAL;

CARCINOGENICITY; COMPUTER MODEL; COVALENT BOND; DRUG DEVELOPMENT; ELECTROPHILICITY; HIGH THROUGHPUT SCREENING; IN VITRO STUDY; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MEDICAL PRACTICE; MUTAGENICITY; NANOTOXICOLOGY; NONHUMAN; PHYSICAL CHEMISTRY; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REPRODUCTIVE TOXICITY; REVIEW; RISK ASSESSMENT; RISK MANAGEMENT; BIOLOGICAL MODEL; COMPUTER SIMULATION; EUROPEAN UNION; HUMAN; TOXICITY TESTING;

COMPUTER SIMULATION; EUROPEAN UNION; HUMANS; MODELS, BIOLOGICAL; NANOSTRUCTURES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RISK ASSESSMENT; TOXICITY TESTS;

EID: 84910631140     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2014.06.027     Document Type: Review

References (49)

1. E. Benfenati The e-Book on QSAR and REACH: Theory, Guidance and Applications 2012
2. European Commission Regulation (EC) No 1907/2006 of The European Parliament and of The Council of 18 December 2006 concerning the Registration, Evaluation. Authorization and Restriction of Chemicals (REACH), establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC Off. J. Eur. Union Lett. 396 2006 1 849
3. S. Van Heerden Recent developments in global regulatory framework in the chemical industry Popul. Plast. Packag. 57 2012 46 50
4. C. Rovida, and T. Hartung Re-evaluation of animal numbers and costs for in vivo tests to accomplish REACH legislation requirements for chemicals: a report by the Transatlantic Think Tank for Toxicology (T(4)) ALTEX 26 2009 187 208
5. J.J. Hornberg Exploratory toxicology as an integrated part of drug discovery. Part I: why and how Drug Discov. Today 2013 10.1016/j.drudis.2013.12.008
6. European Union Regulation (EU) No 528/2012 of The European Parliament and of The Council of 22 May 2012 concerning the making available on the market and use of biocidal products Off. J. Eur. Union Lett. 167 2012 1 123
7. A. Tropsha The importance of being earnest: validation is the absolute essential for successful application and interpretation of QSPR models QSAR Comb. Sci. 22 2003 69 77
8. R.D. Cramer The inevitable QSAR renaissance J. Comput. Aided Mol. Des. 26 2012 35 38
9. G. Patlewicz Use of category approaches, read-across and (Q)SAR: general considerations Regul. Toxicol. Pharmacol. 67 2013 1 12
10. E. Benfenati Using toxicological evidence from QSAR models in practice ALTEX 30 2013 19 40
11. ® Windows, v 4.11 2014 United States Environmental Protection Agency
12. T.M. Martin A hierarchical clustering methodology for the estimation of toxicity Toxicol. Mech. Methods 18 2008 251 266
13. S. Brandmaier The QSPR-THESAURUS: the online platform of the CADASTER project Altern. Lab. Anim. 42 2014 13 24
14. D. Young Are the chemical structures in your QSAR correct? QSAR Comb. Sci. 27 2008 1337 1345
15. H. Zhu Combinatorial QSAR modeling of chemical toxicants tested against Tetrahymena pyriformis J. Chem. Inf. Model. 48 2008 766 784
16. I.V. Tetko Critical assessment of QSAR models of environmental toxicity against Tetrahymena pyriformis: focusing on applicability domain and overfitting by variable selection J. Chem. Inf. Model. 48 2008 1733 1746
17. H. van de Waterbeemd, and E. Gifford ADMET in silico modelling: towards prediction paradise? Nat. Rev. Drug Discov. 2 2003 192 204
18. P.A. Lipinski Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Deliv. Res. 23 1997 3 25
19. M.P. Gleeson Probing the links between in vitro potency, ADMET and physicochemical parameters Nat. Rev. Drug Discov. 10 2011 197 208
20. M. Abou-Gharbia, and W.E. Childers Discovery of Innovative therapeutics: today's realities and tomorrow's vision. 2. Pharma's challenges and their commitment to innovation J. Med. Chem. 2014 10.1021/jm401564r
21. G.R. Bickerton Quantifying the chemical beauty of drugs Nat. Chem. 4 2012 90 98
22. J.C. Arcos, and M.F. Argus Multifactor interaction network of carcinogenesis - a "Tour Guide" J.C. Arcos, Chemical Induction of Cancer. Modulation and Combination Effects 1995 Birkhäuser 1 20
23. B.N. Ames The detection of environmental mutagens and potential carcinogens Cancer 53 1984 2030 2040
24. S.J. Enoch, and M.T. Cronin A review of the electrophilic reaction chemistry involved in covalent DNA binding Crit. Rev. Toxicol. 40 2010 728 748
25. R. Benigni Nongenotoxic carcinogenicity of chemicals: mechanisms of action and early recognition through a new set of structural alerts Chem. Rev. 113 2013 2940 2957
26. I. Sushko ToxAlerts: a Web server of structural alerts for toxic chemicals and compounds with potential adverse reactions J. Chem. Inf. Model. 52 2012 2310 2316
27. T. Ferrari, and G. Gini An open source multistep model to predict mutagenicity from statistical analysis and relevant structural alerts Chem. Cent. J. 29 Suppl 1 2010 S2
28. S. Novotarskyi A comparison of different QSAR approaches to modeling CYP450 1A2 inhibition J. Chem. Inf. Model. 51 2011 1271 1280
29. M.D. Segall, and C. Barber Addressing toxicity risk when designing and selecting compounds in early drug discovery Drug Discov. Today 2014 10.1016/j.drudis.2014.01.006
30. J. Kazius Derivation and validation of toxicophores for mutagenicity prediction J. Med. Chem. 48 2005 312 320
31. M.T. Cronin, and A.P. Worth (Q)SARs for predicting effects relating to reproductive toxicity QSAR Comb. Sci. 27 2008 91 100
32. S. Wu Framework for identifying chemicals with structural features associated with the potential to act as developmental or reproductive toxicants Chem. Res. Toxicol. 26 2013 1840 1861
33. O. Nicolotti Improving quantitative structure-activity relationships through multiobjective optimization J. Chem. Inf. Model. 49 2009 2290 2302
34. A. Vuorinen In silico methods in the discovery of endocrine disrupting chemicals J. Steroid Biochem. Mol. Biol. 137 2013 18 26
35. Y. Tanrikulu The holistic integration of virtual screening in drug discovery Drug Discov. Today 18 2013 358 364
36. L.G. Nashev Virtual screening as a strategy for the identification of xenobiotics disrupting corticosteroid action PLoS ONE 2012 10.1371/journal.pone.0046958
37. Y. Sakuratani Hazard Evaluation Support System (HESS) for predicting repeated dose toxicity using toxicological categories SAR QSAR Environ. Res. 24 2013 351 363
38. P. Mazzatorta Modeling oral rat chronic toxicity J. Chem. Inf. Model. 48 2008 1949 1954
39. Gadaleta, D. et al. A k-NN algorithm for predicting the oral sub-chronic toxicity in the rat. ALTEX (in press), http://dx.doi.org/10.14573/altex.1405091.
40. F.S. Collins Transforming environmental health protection Science 319 2008 906 907
41. D. Fourches Quantitative nanostructure-activity relationship modeling ACS Nano 4 2010 5703 5712
42. P. Lubinski Evaluation criteria for the quality of published experimental data on nanomaterials and their usefulness for QSAR modelling SAR QSAR Environ. Res. 24 2013 995 1008
43. K.L. Dreher Environmental impact of nanotechnology: toxicological assessment of manufactured nanoparticles Toxicol. Sci. 77 2004 3 5
44. T. Puzyn Toward the development of 'nano-QSARs': advances and challenges Small 5 2009 2494 2509
45. T. Puzyn Using nano-QSAR to predict the cytotoxicity of metal oxide nanoparticles Nat. Nanotechnol. 6 2011 175 178
46. J. Liu Identification of possible sources of nanotoxicity from carbon nanotubes inserted into membrane bilayers using membrane interaction quantitative structure-activity relationship analysis Chem. Res. Toxicol. 21 2008 459 466
47. J. Liu Affinity of drugs and small biologically active molecules to carbon nanotubes: a pharmacodynamics and nanotoxicity factor? Mol. Pharm. 6 2009 873 882
48. A. Gissi An alternative QSAR-based approach for predicting the bioconcentration factor for regulatory purposes ALTEX 31 2014 23 36
49. I.V. Tetko Experimental and theoretical studies in the EU FP7 Marie Curie Initial Training Network Project, Environmental ChemOinformatics (ECO) Altern. Lab. Anim. 42 2014 7 11